Thomas E Pack Deceased1021 Hugh Champion Rd, Tryon, NC 28782

6066227, May 23, 2000

Jun 15, 1998

9/097841

Carlton R. Melton - Landrum SC
Thomas E. Pack - Rutherfordton NC

Mohawk Industries, Inc. - Calhoun GA

B29C 6502

1562722

A system for forming a carpet seam including source and take-up carpet roller assemblies and a seaming support having a work surface upon which two carpet sections can be aligned. The seaming support includes a roller and an electric current source for providing an electric current to electrically self-heating thermoplastic bonding tape. The method of the present invention includes the steps of cutting out a defective section of carpet on the seaming support work surface, aligning the leading edge of the resulting front carpet section with trailing edge of the rear carpet section, applying a strip of electrically self-heating thermoplastic bonding tape to the backing side of the carpet, applying an electric current to the tape, and rolling the rejoined carpet onto the take-up roller assembly.

2023000, Jan 5, 2023

Jul 18, 2022

17/813173

- Basel, CH
Magdalena Alonso-Galicia - Durham NC, US
Thomas Pack - Durham NC, US
Julie Rurka - Raleigh NC, US
David Carpenter - Durham NC, US
Melissa Rhodes - Raleigh NC, US

A61K 31/506
A61P 9/12
A61K 9/00

There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day

2020028, Sep 17, 2020

Mar 13, 2020

16/818236

- Basel, CH
David Carpenter - Durham NC, US
Thomas Pack - Durham NC, US
Melissa Rhodes - Raleigh NC, US
Julie Rurka - Raleigh NC, US
Steve Wring - South Boston VA, US

A61K 31/506
A61K 9/00
A61P 9/12

There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.

2020015, May 21, 2020

Nov 15, 2019

16/685165

- Basel, CH
Magdalena ALONSO-GALICIA - Durham NC, US
Thomas PACK - Durham NC, US
Julie RURKA - Raleigh NC, US
David CARPENTER - Durham NC, US
Melissa RHODES - Raleigh NC, US

ALTAVANT SCIENCES GmbH - BASEL

A61K 31/506
A61K 9/00
A61P 9/12

There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day